Vemurafenib Recruiting Phase 2 Trials for Metastatic Melanoma / Metastatic Melanoma, BRAF V600 Mutation Positive Screening

IndicationsStatusPurposePhase
RecruitingScreening2
clinicaltrials.gov IdentifierTitleDrugs